MeSH tree: C08.381.540.140.500
A new study validating the clinical utility of a proprietary pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit—called Immunotherapy Response Score (IRS)—was published in Communications ...
Feb 7, 2023
0
54
Lung cancer claims more lives each year than any other type of cancer worldwide. According to the World Health Organization, an estimated 1.8 million people died of lung cancer in 2020. Current treatments rely on one of two ...
Feb 1, 2023
0
99
New data from a Yale Cancer Center-led clinical trial shows improved rates of survival and reduced risk of recurrence in patients taking osimertinib, a targeted therapy for non-small cell lung cancer (NSCLC). NSCLC is the ...
Jan 31, 2023
0
86
A study published in the January issue of The Journal of Nuclear Medicine reports that approximately one out of every two Medicare patients with non-small cell lung cancer (NSCLC) does not receive the appropriate imaging ...
Jan 18, 2023
0
82
Treatment for lung cancer is rapidly evolving, with new technologies and research-proven procedures. However, a study from Washington University School of Medicine in St. Louis found the quality of care for lung cancer in ...
Jan 18, 2023
0
51
A protein commonly found at high levels in lung cancer cells controls a major immunosuppressive pathway that allows lung tumors to evade immune attack, according to a study led by researchers at Weill Cornell Medicine. The ...
Jan 10, 2023
0
76
The notorious spike protein of SARS-CoV-2, the virus that causes COVID-19, caused lung cancer cells to die in laboratory studies conducted by researchers at RUSH University Medical Center, who recently published their findings ...
Dec 6, 2022
0
154
Regular postsurgical screening is critical for patients with lung cancer, the United States' second most prevalent type of cancer and leading cause of cancer deaths. In cases involving early-stage non small cell lung cancer, ...
Nov 29, 2022
0
51
Hyaluronan (HA) accumulation is associated with tumorigenesis and aggressive tumor behavior. In a new study, researchers Jun Gong, Michelle Guan, Haesoo Kim, Natalie Moshayedi, Sejal Mehta, Galen Cook-Wiens, Brent K. Larson, ...
Nov 9, 2022
0
40
Preliminary data from a phase I clinical trial of a new drug called NVL-520 for patients with non-small cell lung cancer (NSCLC) and other solid tumors, suggest that it may have the potential to both halt tumor growth by ...
Oct 28, 2022
0
66
